Evidence Hub

Oral anticoagulant-proton pump inhibitor interactions: A pharmacovigilance assessment using disproportionality and interaction analyses

Kannan Sridharan, Gowri Sivaramakrishnan

Pharmacy Practice, 2026

Abstract

Objective: Oral anticoagulants operate within a narrow therapeutic window, with upper gastrointestinal bleeding representing a significant safety concern. While proton pump inhibitors (PPIs) have demonstrated gastroprotective properties, existing literature presents conflicting evidence regarding their interactions with oral anticoagulants. Methods: A detailed analysis was conducted using the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database. The study examined interactions between five oral anticoagulants (warfarin, apixaban, dabigatran, edoxaban, and rivaroxaban) and six PPIs (lansoprazole, dexlansoprazole, omeprazole, esomeprazole, pantoprazole, and rabeprazole). A case-non-case disproportionality analysis was employed, utilizing both frequentist and Bayesian data mining algorithms. Interaction Signal Scores were calculated to evaluate interaction strengths. Results: Of 29,163,222 initial reports, 5,222 met inclusion criteria. Significant interactions were identified across multiple anticoagulant-PPI combinations. Notably, dabigatran combined with omeprazole or pantoprazole, and apixaban with most PPIs, demonstrated increased hemorrhagic event risks. Gastrointestinal hemorrhage interactions were most extensive, with significant signals across multiple drug combinations. Certain combinations, like rivaroxaban-esomeprazole, showed protective effects, while others, such as rivaroxaban-rabeprazole, exhibited increased venous…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free